Update on therapy of atopic dermatitis

被引:47
作者
Hanifin, JM [1 ]
Tofte, SJ [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Dermatol L468, Portland, OR 97201 USA
关键词
atopic dermatitis; bathing/moisturizing; trigger factors;
D O I
10.1016/S0091-6749(99)70054-0
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis (AD) is complicated and often difficult to manage. Effective therapy is commonly impeded by 3 ambivalencies: (1) prioritization of skin care versus allergy treatment; (2) uncertainty about optimal bathing and moisturizing, and (3) hesitation about the use of adequate topical corticosteroid therapies. With a confident, well-planned approach, effective therapy management may be achieved. On initial assessment, an evaluation form is a tool to keep the focus on important history and physical features critical for the diagnosis and to review trigger factors and past therapies. Patients and parents must be educated to become more aware of the trigger factors that may lead to an exacerbation of their disease. Errors in bathing and moisturizing are the major cause of persistent AD, and the confusing parades that water is both good and bad for the skin must be resolved to achieve therapeutic success, Avoidance/approach conflicts regarding recommendations of topical steroid use has a detrimental effect on patient outcomes, With the proper use of mid-strength topical agents and with the recent development of topical macrolides for use in AD, effective management for this disease can be realized.
引用
收藏
页码:S123 / S125
页数:3
相关论文
共 15 条
[1]   A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children [J].
Boguniewicz, M ;
Fiedler, VC ;
Raimer, S ;
Lawrence, ID ;
Leung, DYM ;
Hanifin, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :637-644
[2]   1,4-cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma [J].
Christensen, SB ;
Guider, A ;
Forster, CJ ;
Gleason, JG ;
Bender, PE ;
Karpinski, JM ;
DeWolf, WE ;
Barnette, MS ;
Underwood, DC ;
Griswold, DE ;
Cieslinski, LB ;
Burman, M ;
Bochnowicz, S ;
Osborn, RR ;
Manning, CD ;
Grous, M ;
Hillegas, LM ;
Bartus, JO ;
Ryan, MD ;
Eggleston, DS ;
Haltiwanger, RC ;
Torphy, TJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (06) :821-835
[3]   Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis [J].
Hanifin, JM ;
Chan, SC ;
Cheng, JB ;
Tofte, SJ ;
Henderson, WR ;
Kirby, DS ;
Weiner, ES .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (01) :51-56
[4]   MONOCYTE PHOSPHODIESTERASE ABNORMALITIES AND DYSREGULATION OF LYMPHOCYTE FUNCTION IN ATOPIC-DERMATITIS [J].
HANIFIN, JM ;
CHAN, SC .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 105 (01) :S84-S88
[5]  
HANIFIN JM, 1986, CLIN REV ALLERG, V4, P43
[6]  
HANIFIN JM, 1992, MAST CELL HLTH DIS, P639
[7]  
HANIFIN JM, 1993, ALLERGY PRINCIPLES P, P1581
[8]  
Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3
[9]   ATOPIC-DERMATITIS IN CHILDREN - WHO CARES QUESTIONABLE WHO PAYS [J].
LAPIDUS, CS ;
SCHWARZ, DF ;
HONIG, PJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (05) :699-703
[10]   The occurrence of atopic dermatitis in North Europe: An international questionnaire study [J].
Larsen, FS ;
Diepgen, T ;
Svensson, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (05) :760-764